Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Saint Herblain (France), July, 11 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will lift the temporary...
-
VALNEVA Déclaration d’actions et de droits de vote 30 juin 2025__________________________________________________________________________________________ Dénomination sociale : VALNEVAAdresse du...
-
VALNEVA Declaration of shares and voting rights June 30, 2025__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue...
-
New York, USA, June 26, 2025 (GLOBE NEWSWIRE) -- Global Medical Drones Market Gearing Up for Outstanding Expansion at a CAGR of ~17% by 2032 | DelveInsight Several key factors are fueling the...
-
Saint-Herblain, France, le 26 juin 2025 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui un accord exclusif avec CSL Seqirus, l'une des...
-
Saint-Herblain, France, June 26, 2025 – Valneva SE, (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced an exclusive agreement with CSL Seqirus, one of the world’s...
-
Saint-Herblain (France), le 25 juin 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que toutes les résolutions recommandées par son...
-
Saint-Herblain (France), June 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Board of Directors...
-
New York, USA, June 19, 2025 (GLOBE NEWSWIRE) -- Global Protein Expression Market to Observe Growth at a CAGR of ~8% by 2032 | DelveInsight The protein expression market is primarily driven by the...
-
IXCHIQ® was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV)Antibody levels remained high after six months in both dose groups,...